Acoustic Pharmaceutical CDK4/6 inhibitors were approved for bone marrow protection in clinical chemotherapy patients

Trilaciclib is a pioneering, short-acting CDK4/6 inhibitor that induces short and reversible G1 cell cycle stagnation in CDK4/6-dependent cells, reducing DNA damage and apoptosis after exposure to chemotherapy.
as a bone marrow protector, Trilaciclib protects the patient's bone marrow from chemotherapy and improves the patient's prognostics.
note that other CDK4/6 inhibitors currently on the market do not have this bone marrow protection effect based on current clinical data.
According to insight database, G1 has launched seven clinical trials abroad for Trilaciclib, with adaptations including small cell lung cancer, colorectal cancer, breast cancer, etc.;
from: Insight Database () At the 2019 ASCO conference, G1 published randomized, double-blind, multi-center Phase 2 study data for treated broad-term SCLC patients who were randomly treated with topological trilaciclib or placebo therapy, with a total of 91 patients randomized.
results showed that the use of trilaciclib significantly reduced the occurrence of severe neutral granulocyte reduction in patients treated with topologically 1.5 mg/m2. .6%(P), P=0.016,' and reduced its duration in the first cycle by 2 days (T) to 8 days (P), P=lt;0.0001.
5 weeks of treatment, fewer patients in the trilaciclib treatment group received red blood cell infusions, granulocyte group stimulation factor (GCSF) therapy and other causes of reduced dose of treatment.
In addition, Trilaciclib's mTNBC Phase II clinical study of tricyclic breast cancer also showed a statistically significant improvement in OS in patients who received Trilaciclib plus chemotherapy combination therapy in 102 patients who had previously received 0-2 therapies for metastasis breast cancer compared to female patients treated with chemotherapy alone (Gisitalbin/Carp platinum).